Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
New Multi-Ancestry Polygenic Score Improves BMI and Obesity Prediction Across the Lifespan
Added: 3 months ago Source:  Radcliffe CVRM
A new multi-ancestry polygenic score (PGS) for body mass index (BMI), developed using genetic data from over 5.1 million people, substantially improves the prediction of obesity across the life course compared to previous scores.¹ The research, which drew data from the GIANT consortium and 23andMe, demonstrates particular value in predicting obesity risk from early childhood and in understanding… View more

Cardiovascular Renal Metabolic

Demographic
Chan Hong
Research Area(s) / Expertise:

Expertise

Heart Failure
Job title: Pharmacist
Mr Chan Hong is an ambulatory Pharmacist in National Heart Centre Singapore (NHCS). He is currently involved in managing ambulatory clinics in areas of anticoagulation, smoking cessation and heart failure management. He is a keen advocate for patient empowerment and education to improve disease prevention and public health. He is currently involved in the formulation and review of Patient… View more
Obesity and CKD: The Dual Epidemic in Cardiovascular Health
Author(s): Christopher Henry Grant , Samira Bell Added: 3 weeks ago

Cardiovascular Renal Metabolic

Prevention & Chronic Conditions
Research Area(s) / Expertise:

Expertise

Heart Failure
Specialist in Internal Medicine with special training in hypertension and dyslipidemia and a genuine passion for preventive medicine; lecturer at the University of Zürich and PhD in cardiovascular research. Head of the hypertension and dyslipidemia facilities of the heart center and of the smoking cessation clinic of the university Hospital Zurich. Her research focuses on vascular research … View more
ACC 25 Late-Breaking Discussion: The SOUL Trial
Author(s): Harriette Van Spall , Darren McGuire Added: 7 months ago
ACC 25 - SOUL shows oral semaglutide was superior to placebo in reducing the incidence of 3-point MACE in patients with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease.Late-breaker host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Dr Darren McGuire (UT Southwestern Medical Center, Dallas, US) to discuss the findings from the… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
ADA 25: Final Results of the CATALYST Trial
Author(s): Added: 4 months ago
ADA 2025 - Final results from the CATALYST trial show mifepristone significantly improved glucose control in patients with hypercortisolism and difficult-to-control diabetes.We are joined by Dr John Buse (University of North Carolina, Chapel Hill, US) to discuss phase 4 results from CATALYST (NCT05772169), a randomised, placebo-controlled, multi-center trial investigating the safety and efficacy… View more

Cardiovascular Renal Metabolic
Tirzepatide Benefits in HFpEF Consistent Across Obesity Levels, SUMMIT Analysis Shows
Added: 3 months ago Source:  Radcliffe CVRM
A secondary analysis of the SUMMIT trial has found that the benefits of tirzepatide on reducing the risk of cardiovascular death or worsening heart failure (HF) are consistent across all levels of obesity in patients with heart failure with preserved ejection fraction (HFpEF).¹ However, patients with a higher baseline body mass index (BMI) experienced greater improvements in exercise capacity and… View more

Cardiovascular Renal Metabolic

Heart Failure
THT 2025: The SUMMIT Trial
Author(s): Barry Borlaug Added: 8 months ago
THT Conference 2025 - Outcomes assessing the effect of obesity severity on tirzepatide in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) show that patients on tirzepatide with a greater reduction in BMI and baseline waist-to-height ratio had greater improvements in exercise capacity and KCCQ quality of life scores.Dr Barry Borlaug (Mayo Clinic and Foundation,… View more

Heart Failure

Prevention & Chronic Conditions
ESC HF 25: The PRAISE-HFrEF Study
Author(s): Varun Sundaram Added: 6 months ago
ESC HF 25 - Safety outcomes from PRAISE-HFrEF show that glucagon-like peptide-1 receptor agonism (GLP-1 RA) treatment for heart failure with reduced ejection fraction (HFrEF) and obesity was not associated with increased risk of heart failure hospitalisation or mortality compared to placebo, with greater benefits observed in patients with higher BMI.Dr Varun Sundaram (Case Western Reserve… View more

Cardiovascular Renal Metabolic

Heart Failure
Oral P2Y12 Inhibitors and Drug Interactions
Author(s): Elisabetta Bigagli , Jacopo Angelini , Alessandro Mugelli , et al Added: 5 months ago

Anticoagulation

Prevention & Chronic Conditions